Boston Scientific BSX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net sales of reportable segments by Business | ||||||
| Cardiovascular | $13.64B+18.2% | $13.29B+22.6% | $12.8B+24.9% | $12.22B+26.2% | $11.54B+25.2% | |
| MedSurg | $6.93B+11.3% | $6.84B+13.4% | $6.67B+13.4% | $6.44B+12.4% | $6.22B+11.4% | |
| Net Sales by Business | ||||||
| Cardiovascular | $13.67B+19.9% | $13.25B+23.2% | $12.72B+25.9% | $12.1B+26.7% | $11.4B+24.5% | |
| MedSurg | $6.95B+12.8% | $6.82B+13.8% | $6.64B+14.1% | $6.39B+12.6% | $6.16B+10.9% | |
| Total assets of reportable segments by Business | ||||||
| Cardiovascular | $31.55B— | $30.71B— | $29.79B— | —— | —— | |
| MedSurg | $13.84B— | $13.24B— | $12.94B— | —— | —— | |
| Other segment items by Business | ||||||
| Cardiovascular | $26M+23.8% | $25M+31.6% | $23M+16.5% | $22M+7.3% | $21M-1.2% | |
| MedSurg | $20M+33.3% | $21M+50.0% | $24M+71.4% | $19M0.0% | $15M-25.0% | |
| Operating Income (Loss), Adjusted by Business | ||||||
| Cardiovascular | $4.38B+20.7% | $4.32B+33.7% | $4.18B+43.8% | $3.91B+48.4% | $3.62B+48.5% | |
| MedSurg | $2.27B+6.3% | $2.28B+9.0% | $2.26B+13.6% | $2.22B+14.1% | $2.14B+13.2% | |
| Selling, general and administrative expenses, percentage of net sale by Business | ||||||
| Cardiovascular | 82.5%— | 82.8%— | —— | —— | —— | |
| Cost of products sold by Business | ||||||
| Cardiovascular | $4.09B+15.9% | $3.95B+15.7% | $3.81B+19.1% | $3.72B+21.3% | $3.53B+20.8% | |
| MedSurg | $1.96B+15.0% | $1.92B+16.1% | $1.85B+18.1% | $1.77B+16.9% | $1.71B+14.9% | |
| Cost of products sold, percentage of net sale by Business | ||||||
| Cardiovascular | 89.8%— | 88.6%— | —— | —— | —— | |
| MedSurg | 84.2%+2.3pp | 83.1%+1.3pp | 82.9%-5.4pp | 82.5%+15.2pp | 81.9%+34.7pp | |
| Research and development expenses, percentage of net sale by Business | ||||||
| Cardiovascular | 29.7%+3.0pp | 28.9%+1.9pp | 28.6%-0.7pp | 27.4%+4.6pp | 26.7%+10.1pp | |
| MedSurg | 22.1%-0.7pp | 22.1%-0.8pp | 22.1%-2.7pp | 22.2%+3.1pp | 22.8%+9.3pp | |
| Selling, general and administrative expenses by Business | ||||||
| Cardiovascular | $3.78B+13.3% | $3.69B+15.3% | $3.58B+18.3% | $3.45B+17.8% | $3.33B+18.0% | |
| MedSurg | $2.17B+14.6% | $2.12B+16.7% | $2.04B+17.2% | $1.95B+13.9% | $1.89B+13.1% | |
| Impact of foreign currency fluctuations and purchase price and other adjustments by Business | ||||||
| MedSurg | $31M— | $53M— | $31M— | —— | —— | |
| Research and development expenses by Business | ||||||
| Cardiovascular | $1.37B+32.5% | $1.31B+33.8% | $1.21B+32.0% | $1.12B+25.8% | $1.03B+18.5% | |
| MedSurg | $513M+7.8% | $507M+9.7% | $497M+12.7% | $482M+10.8% | $476M+11.2% | |
| Goodwill by Business | ||||||
| Cardiovascular | $42.21B+10.5% | $41.49B+11.0% | $40.53B+10.1% | $39.68B+9.9% | $38.19B+5.8% | |
| MedSurg | $30.9B+20.4% | $30.42B+29.4% | $30.2B+41.2% | $27.86B+35.0% | $25.67B+29.0% | |
| Depreciation by Business | ||||||
| Cardiovascular | $366M+16.2% | $355M+17.2% | $341M+22.8% | $327M+21.8% | $315M+19.7% | |
| MedSurg | $117M+4.5% | $115M+5.5% | $115M+10.8% | $113M+10.2% | $112M+10.6% | |
| Goodwill acquired by Business | ||||||
| Cardiovascular | $685M-16.5% | $890M+44.7% | $859M— | $1.42B— | $820M— | |
| MedSurg | $447M— | $173M— | $2.31B— | —— | —— | |
| Net Sales by Product | ||||||
| Cardiac Rhythm Management | $2.33B+2.2% | $2.33B+2.4% | $2.31B+2.1% | $2.3B+1.7% | $2.28B+1.6% | |
| Electrophysiology | $3.5B+50.0% | $3.33B+74.6% | $3.08B+106% | $2.75B+137% | $2.33B+153% | |
| Endoscopy | $2.98B+9.6% | $2.92B+8.5% | $2.85B+7.8% | $2.78B+7.2% | $2.72B+6.7% | |
| Neuromodulation | $1.25B+11.3% | $1.2B+8.6% | $1.17B+8.6% | $1.14B+10.2% | $1.12B+12.3% | |
| Urology | $2.72B+17.3% | $2.71B+23.1% | $2.62B+25.0% | $2.47B+20.7% | $2.32B+15.5% | |
| Watchman | $2.04B+27.7% | $1.96B+29.2% | $1.84B+26.9% | $1.7B+22.6% | $1.6B+20.3% | |
| Net Sales by Geography | ||||||
| Asia-Pacific | $3.18B+16.2% | $3.08B+14.7% | $2.98B+13.8% | $2.86B+12.4% | $2.74B+9.6% | |
| Europe, Middle East and Africa | $3.54B+8.1% | $3.45B+6.9% | $3.35B+6.4% | $3.33B+9.3% | $3.27B+11.0% | |
| Latin America and Canada | $708M+12.2% | $678M+8.5% | $654M+5.8% | $638M+5.5% | $631M+8.2% | |
| U.S. | $13.19B+20.8% | $12.86B+26.0% | $12.37B+29.8% | $11.67B+29.2% | $10.91B+25.7% | |
| Long-Lived Assets by Geography | ||||||
| Costa Rica | $2.44B— | $2.36B— | $2.25B— | —— | —— | |
| Ireland | $2.91B— | $2.81B— | $2.69B— | —— | —— | |
| U.S. | $7.21B— | $6.78B— | $6.33B— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
